We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
IL‐18: A potential inflammation biomarker in Wiskott–Aldrich syndrome.
- Authors
Rivers, Elizabeth; Hong, Ying; Bajaj‐Elliott, Mona; Worth, Austen; Thrasher, Adrian J.
- Abstract
Use of recombinant IL-18bp or anti-IL-18 therapies may therefore be useful for treatment of inflammation in WAS, and further studies of larger cohorts evaluating IL-1 family cytokines are warranted. Analysis of serum cytokine levels in Wiskott-Aldrich syndrome patients pre- and post- treatment reveals IL-18 as a stable and reliable marker of inflammation. This treatment inhibits signaling through the IL-1R complex, the receptor for IL-1 and IL-1 (but not IL-18).
- Subjects
WISKOTT-Aldrich syndrome; ECZEMA; GRAFT versus host disease
- Publication
European Journal of Immunology, 2021, Vol 51, Issue 5, p1285
- ISSN
0014-2980
- Publication type
Article
- DOI
10.1002/eji.202049024